C-IG6JAugustine Therapeutics
HDAC6 inhibition, non-hydroxamate chemotype
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-IG6J
C-IG6JC-IG6JHDAC6 inhibition, non-hydroxamate chemotype
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Augustine Therapeutics HDAC6 inhibition, non-hydroxamate chemotype
Augustine Therapeutics is developing a portfolio of selective HDAC6 inhibitors for chronic disease. Its chemistry uses a novel non-hydroxamate, non-hydrazine producing chemotype designed to avoid off-target toxicity while preserving beneficial non-catalytic HDAC6 functions. The company is advancing peripherally restricted and CNS-penetrant programs for neurologic, neuromuscular, and cardiometabolic diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Augustine Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (3 programs at undisclosed).…
Source: Deterministic